Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cloud DX (CDX) announces a brokered private placement of convertible debenture units for gross proceeds of up to $3,000,000
  • The agents have an option to sell up to 450 additional convertible debenture units for maximum aggregate gross proceeds of $3,450,000
  • The company intends to use the net proceeds of the offering for sales, marketing, research and development
  • The offering is expected to close on or about September 23, 2021
  • Cloud DX Inc. (CDX) opened trading at C$0.23 per share

Cloud DX (CDX) has announced a brokered private placement of up to 3,000 convertible debenture units for gross proceeds of up to $3,000,000.

Echelon Wealth Partners Inc. has agreed to act as lead agent and sole book runner on behalf of a syndicate of investment dealers. The agents have an option to sell up to 450 additional convertible debenture units for maximum aggregate gross proceeds of $3,450,000.

Each debenture unit will consist of $1,000 principal amount unsecured convertible debenture and 1,430 common share purchase warrants. The debentures will mature 36 months from the date of issuance and shall bear interest at a rate of 10% per annum. Interest will be payable quarterly on the last business day of each quarter, commencing on December 31, 2021.

The company intends to use the net proceeds of the offering for sales, marketing, research and development, and for general working capital purposes.

The offering is expected to close on or about September 23, 2021.

Accelerating virtual healthcare’s future, Cloud DX is making healthcare better for everyone. The company’s Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable ageing in place and deliver hospital-quality post-surgical care.

Cloud DX Inc. (CDX) opened trading at C$0.23 per share.

More From The Market Herald
Levitee Labs - CEO, Pouya Farmand.

" Levitee Labs (CSE:LVT) partners with Adracare for addiction and mental health support

Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services.

" Cardiol Therapeutics (TSX:CRDL) expands phase II/III trial of CardiolRx

Cardiol Therapeutics (CRDL) is expanding its LANCER trial to include several hospital centers in Brazil, Mexico, and Canada.

" XORTX Therapeutics (CSE:XRX) closes public offering

XORTX Therapeutics (XRX) announced the closing of a US$12M public offering.

" Marvel Biosciences (TSXV:MRVL) updates the status of its MB-204 manufacturing efforts

Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.